About this trial
The molecular characteristics of ischemic stroke with phlegm-heat syndrome and candidate biomarkers were identified based on multi-omics data. The main purpose of this study is to validate the molecular characteristics and biomarkers of phlegm-heat syndrome in ischemic stroke, and to demonstrate the association of biomarkers with clinical outcomes.
Eligibility criteria
Qualifiers
Acute ischemic stroke, were confirmed by magnetic resonance imaging (MRI).
Symptom onset within 72 hours.
Diagnosis of phlegm-heat syndrome or non-phlegm-heat syndrome.
Male or female ≥ 50 years and ≤ 80 years.
Disqualifiers
Planned or already receiving intravenous thrombolysis or endovascular treatment.
Acute infectious diseases or acute exacerbations of chronic diseases within one month before enrollment.
Patients with previous stroke.
Renal or hepatic insufficiency, tumors, immune diseases, severe underlying diseases.
Trial design
Treatments tested in this trial
- Not listed